Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04684914 · ClinicalTrials.gov registry record · Phase 2
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
A Phase 2 study, sponsored by Altimmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT04684914 is a Phase 2 study that was terminated before completion, run by Altimmune. The registered enrollment target is 87 participants.
The verdict
NCT04684914, a Phase 2 study, was terminated before completion, sponsored by Altimmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive chronic hepatitis B (CHB) and low hepatitis B surface antigen (HBsAg) levels.
Interventions
- DRUG Placebo
- BIOLOGICAL HepTcell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2020-12-26 |
| Est. Completion | 2024-04-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04684914
The ClinicalTrials.gov registry entry for NCT04684914 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04684914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04684914 about?
NCT04684914 is a clinical study titled "HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)". A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive chronic hepatitis B (CHB) and low hepatitis B surface antigen (HBsAg) levels.
What is the current status of trial NCT04684914?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2020-12-26. Estimated completion is 2024-04-17.
What interventions are being tested in trial NCT04684914?
The interventions under investigation include: Placebo (DRUG), HepTcell (BIOLOGICAL).
Who is sponsoring clinical trial NCT04684914?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.